UK Markets closed

DBV Technologies S.A. (DBVT)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
2.7200-0.0900 (-3.20%)
At close: 04:00PM EST
2.7000 -0.02 (-0.74%)
After hours: 04:32PM EST

DBV Technologies S.A.

177-181 Avenue Pierre Brossolette
Montrouge 92120
33 1 55 42 78 78

Full-time employees97

Key executives

NameTitlePayExercisedYear born
Mr. Daniel TasséCEO & Director1.1MN/A1960
Mr. Sébastien RobitailleChief Financial Officer291.82kN/A1970
Dr. Pharis MohideenChief Medical Officer625.26kN/A1965
Dr. Pierre-Henri BenhamouCo-Founder & Member of Scientific Advisory BoardN/AN/A1955
Mr. Pascal WotlingChief Technical Operations OfficerN/AN/AN/A
Anne PollakHead of Investor RelationsN/AN/AN/A
Ms. Michele F. RobertsonChief Legal OfficerN/AN/AN/A
Joseph BeckerVP of Global Corp. CommunicationsN/AN/AN/A
Ms. Caroline DaniereChief HR Officer & Chief of StaffN/AN/A1975
Dr. Wence AgbotounouChief Clinical Trial Officer & Sr. VPN/AN/AN/A
Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults. The company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of Immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA) and milk-induced eosinophilic esophagitis; Viaskin Egg, a pre-clinical stage product for the treatment of hen's egg allergy; and booster vaccine for Bordetella pertussis. Its other earlier stage research programs include a vaccine for the respiratory syncytial virus, as well as treatments for Crohn's disease, celiac disease, and type I diabetes. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was founded in 2002 and is headquartered in Montrouge, France.

Corporate governance

DBV Technologies S.A.’s ISS governance QualityScore as of 1 July 2021 is 9. The pillar scores are Audit: 7; Board: 9; Shareholder rights: 1; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.